Meeting Highlights Information Registration Visa Letter Application Programme Overview Exhibition Virtual Exhibition Hotels Exhibition Virtual Exhibition Satellite Programme


Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Evaluation of progression in keratoconus patients over 40 years of age

Poster Details


First Author: N.Yesilirmak TURKEY

Co Author(s): O. Sarac   N. Ugurlu   M. Caglayan   S. Oner   N. Cagil        

Abstract Details

Purpose:

To evaluate the progression in keratoconus patients over 40 years of age, who did not received any treatment.

Setting:

Yildirim Beyazit University, Ankara State Hospital

Methods:

Patients who were diagnosed with keratoconus over the age of 40 but had not received any treatment before and had at least 1-year follow-up period  were included in this study. The best corrected visual acuity (BCVA), manifest refraction, cylinder, spherical equivalent and topographical data (K1, K2, Kavg, Kmax, central corneal thickness, thinnest corneal thickness, anterior elevation, posterior elevation, corneal volumes) were recorded.

Results:

Sixty-one eyes of 31 patients were included.The mean age was 44,2±4,9 years at first visit and 47,6±5,5 years at last visit. The mean follow-up was 35,4±14,6 months. The mean BCVA levels at the first and last visits were 0,10±0,18 and 0,12 ± 0,18 logMAR, respectively(p = 0,49). There were no statistically significant changes in the manifest refraction, cylinder values, spherical equivalent, mean K1, K2 and Kavg(p>0.05). There was a significant change in Kmax(p=0,02). Nine patients had regression while the others were stable. Other topographical measurements were not significantly different between the first and last visit(p>0.05).

Conclusions:

No progression was seen in keratoconus patients diagnosed over the age of 40 during the follow-up period. Some of the patients may even show regression due to the spontaneous decrease in their Kmax values. Other topographical and refractive parameters, and visual acuity level remained stable.

Financial Disclosure:

None

Back to Poster listing